| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 12, 2020STS101 EMERGE™ Phase 3 efficacy trial remains on track with announcement of topline data expected in second half of 2020
South San Francisco, CA, May 12, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter 2020 and...
-
Apr 28, 2020Satsuma Pharmaceuticals to Host Key Opinion Leader Event: STS101 and the Acute Treatment of Migraine
South San Francisco, CA, April 28, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, announced today that it will host a Key Opinion Leader (KOL)...
-
Mar 10, 2020On track to announce topline data in second half of 2020 from Phase 3 EMERGE™ efficacy trial evaluating STS101 for the acute treatment of migraine
SOUTH SAN FRANCISCO, Calif., March 10, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today reported financial results for the...
-
Mar 5, 2020
South San Francisco, CA, March 5, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced the appointment of Rob Janosky to the newly...
-
Feb 18, 2020
South San Francisco, CA, February 18, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, President and Chief...
-
Jan 28, 2020
South San Francisco, CA, January 28, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that Phase 1 trial results detailing...
-
Nov 26, 2019
South San Francisco, CA, November 26, 2019 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, Satsuma President and...
-
Nov 12, 2019Completed upsized initial public offering of $90.8 million in gross proceeds
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today reported financial results for the...
-
Sep 17, 2019
Satsuma Pharmaceuticals, Inc. ("Satsuma" or the "Company") (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute...
-
Sep 12, 2019
Satsuma Pharmaceuticals, Inc. ("Satsuma" or the "Company") (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute...
-
Sep 3, 2019
Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine,...
-
Sep 3, 2019
Satsuma Pharmaceuticals, Inc. ("Satsuma"), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced...
-
Aug 22, 2019
Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a clinical-stage biopharmaceutical company, today announced dosing of the first patient...
-
Jul 8, 2019-- Favorable Pharmacokinetic, Safety, and Tolerability Results Support Advancing STS101 into Pivotal Phase 3 Efficacy Trial
Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a late-stage biopharmaceutical company developing STS101, (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine,...
-
May 29, 2019-- Commercial leader brings recent migraine space experience to Satsuma as it advances lead product candidate STS101 into Phase 3 development --
Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a Phase 3-stage biopharmaceutical company developing STS101, (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine,...
-
Apr 24, 2019Funding supports Phase 3 development of STS101 for the acute treatment of migraine, including pivotal Phase 3 efficacy trial with planned initiation in Q3 2019
Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a clinical-stage biopharmaceutical company developing STS101, (dihydroergotamine (DHE) nasal powder) for the acute treatment of...
-
Apr 1, 2019
Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company") today announced that John Kollins, the Company's President and Chief Executive Officer, will provide a corporate overview at the Needham...
-
Feb 20, 2019- STS101 for the acute treatment of migraine demonstrates highly differentiated pharmacokinetic (PK) profile in Phase 1 clinical trial
Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a clinical-stage biopharmaceutical company, today provided a corporate update, including recent progress with its development of STS101...
-
Feb 14, 2019
Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company") today announced that it will participate in two upcoming investor conferences: 8th Annual SVB Leerink Global Healthcare Conference on...
-
Jan 5, 2017-- $12 Million Series A financing supports development of best-in-class therapy for acute migraine that incorporates novel and proprietary SNBL nasal drug delivery technology --
Satsuma Pharmaceuticals, Inc., a leader in developing best-in-class therapies to address the unmet needs of migraine sufferers, today announced the closing of a $12 million Series A financing...